For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Pulmonary Embolism - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Pulmonary Embolism Understanding
Pulmonary Embolism: Overview
Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.
"Pulmonary Embolism - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.
Pulmonary Embolism Emerging Drugs Chapters
This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Embolism Emerging Drugs
- Recombinant staphylokinase: Supergene
Recombinant staphylokinase contains forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.
- Recombinant human prourokinase: Tasly Pharmaceuticals
Recombinant human prourokinase is being developed by Tasly Pharmaceuticals, for the treatment of myocardial infarction, stroke and pulmonary embolism. Human pro-urokinase, is a single chain structure urokinase-type plasminogen activator, prepared via recombinant DNA technology. The drug is in Phase II clinical studies for the treatment of pulmonary embolism.
Further product details are provided in the report ..
Pulmonary Embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pulmonary Embolism
There are approx. 5+ key companies which are developing the therapies for Pulmonary Embolism. The companies which have their Pulmonary Embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.
DelveInsight's report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Pulmonary Embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pulmonary Embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.
Pulmonary Embolism Report Insights
- Pulmonary Embolism Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pulmonary Embolism Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pulmonary Embolism drugs?
- How many Pulmonary Embolism drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary Embolism and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daiichi Sankyo Company
- Tasly Pharmaceuticals
- Recombinant staphylokinase
- DS 1040
- Recombinant human prourokinase